UTRECHT, The Netherlands, April 19, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage
immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the Company will
report full year 2017 financial results on Thursday, April 26, 2018. Merus’ management team will host a conference call and audio
webcast at 8:30 a.m. ET on Thursday, April 26, 2018, to discuss the financial results and recent clinical and corporate
developments.
To participate in the call, please dial (877) 260-1463 (U.S.) or (706) 643-5907 (international) and reference conference ID
6184636. A live webcast will be available on the Investors page of the Company's website, http://www.merus.nl. An archived webcast
replay will be available for 90 days.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics,
referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard
processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human
monoclonal antibodies, such as long half-life and low immunogenicity. Merus’ most advanced bispecific antibody candidate, MCLA-128,
is being evaluated in a Phase 2 combination trial in two metastatic breast cancer populations. MCLA-128 is also being evaluated in
a Phase 1/2 clinical trial in gastric, ovarian, endometrial and non-small cell lung cancers. Merus’ second most advanced bispecific
antibody candidate, MCLA-117, is being developed in a Phase 1 clinical trial in patients with acute myeloid leukemia. The Company
also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed
to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, as well
as MCLA-145, which is designed to bind to PD-L1 and a non-disclosed second immunomodulatory target, which is being developed in
collaboration with Incyte Corporation. For additional information, please visit Merus’ website, www.merus.nl.
Contacts:
Investors:
Kimberly Minarovich
+1 646-368-8014
kimberly@argotpartners.com
Media:
David Rosen
+1 212-600-1902
David.rosen@argotpartners.com
